Litigation Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)
Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)
| Docket | 1:20-cv-00110-IMK | Date Filed | 2020-06-09 |
| Court | District Court, N.D. West Virginia | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Irene Patricia Murphy Keeley |
| Jury Demand | None | Referred To | |
| Patents | 8,318,802; 8,598,227 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc.
Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-06-09 | 143 | Memorandum & Opinion | Actelion”), U.S. Patent Nos. 8,318,802 (the “’802 patent”) and 8,598,227 (the “’227 patent”) (collectively…CONSTRUCTION This patent infringement case involves two United States Patents owned by Actelion Pharmaceuticals… “It is a bedrock principle of patent law that the claims of a patent define the invention to which the…When construing patent claims, then, a court must consider the context of the entire patent, including both…unasserted claims. Id. at 1314. Because a patent will ordinarily use patent terms consistently, “the usage of | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
